What Is a Pathogenic Variant? ACMG/AMP classification

📍Key Takeaways

1. A pathogenic variant is one with sufficient evidence to conclude it causes a disease—”a variant is present” and “this variant is the cause” are two different things.
2. The ACMG/AMP five-tier system (Pathogenic, Likely pathogenic, VUS, Likely benign, Benign) weighs population, computational, functional, and segregation evidence; a VUS alone is never a basis for diagnosis.
3. Because classification is a dynamic judgment that shifts as evidence accumulates, periodic reanalysis—especially for a reported VUS—is a practical way to raise the diagnostic yield.

When a genetic test report comes back reading “pathogenic variant detected,” it falls to the clinician to explain what that single line actually means for the patient. A pathogenic variant is the starting point for interpreting a result and often the pivot on which diagnosis and downstream management turn. This article walks through the definition of a pathogenic variant, the classification framework behind it, and how to read the report phrases that are most often confused.

Defining a Pathogenic Variant

A pathogenic variant is a genetic change for which there is sufficient evidence to conclude that it causes a particular disease. The key distinction is that “a variant is present” and “this variant causes the disease” sit on two different levels. Every human genome carries millions of variants, and the vast majority have no effect on health. Pathogenicity is never decided by the variant alone; it is judged by weighing several classes of evidence together—population frequency, computational predictions, functional studies, and segregation within families.

The ACMG 5-Tier Classification System

The framework adopted as the standard by clinical laboratories worldwide is the five-tier system jointly issued in 2015 by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP). Variants are sorted, according to the strength of available evidence, into five categories: Pathogenic, Likely pathogenic, Uncertain significance (VUS), Likely benign, and Benign. Each category is reached by combining criteria drawn from population, computational, functional, and segregation data. This shared terminology lets laboratories and clinicians communicate results in a single common language.

How Likely Pathogenic Differs from a VUS

Likely pathogenic describes a variant with substantial—but not the highest possible—evidence supporting a disease-causing role. In practice, likely pathogenic variants are frequently acted upon much as pathogenic ones are in clinical decision-making. A VUS, by contrast, is a variant for which the evidence is insufficient to call it either pathogenic or benign, and it should not on its own serve as a basis for diagnosis. It is essential to understand that a VUS is not a fixed state but a provisional call that may be reclassified as new evidence accumulates.

“Pathogenic Variant Detected” vs. “No Pathogenic Variant Detected”

When a report states that a pathogenic variant was detected, you still need to confirm whether that variant explains the patient’s phenotype and is consistent with the expected mode of inheritance. Conversely, a result of “no pathogenic variant detected” does not fully rule out a genetic condition. A causative variant may go unidentified for many reasons—the scope of the test, variant types that are difficult to detect with current technology, or genes not yet linked to disease. The meaning of a negative result must be interpreted within the context of the test method and the clinical picture.

Importance of Reanalysis

Variant classification is not a fixed conclusion but a dynamic judgment that shifts as evidence accumulates. A VUS today may be reclassified as likely pathogenic in the future through new literature and data—and the reverse is equally possible. For undiagnosed cases, particularly those with a reported VUS, periodic reanalysis is therefore a practical strategy for raising the diagnostic yield.

---

3billion’s WGS and WES include reanalysis at no extra cost and with no separate request required. Click below to see which test best fits your patient and what each test does best.

---

References

1. Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. 2015. https://doi.org/10.1038/gim.2015.30
2. Lyon E, et al. An Educational Assessment of Evidence Used for Variant Classification: A Report of the Association for Molecular Pathology. 2022. https://doi.org/10.1016/j.jmoldx.2021.12.014
3. National Human Genome Research Institute (NHGRI). Pathogenic Variant — Genetics Glossary. https://www.genome.gov/genetics-glossary/Pathogenic-Variant